The relevant disclosure is attached with respect to Audited Financial Results for the year ended March 31, 2025.
Awaiting price reaction for this filing.
Fortis Healthcare reported standalone revenue from operations of ₹1,445.89 crore for FY25, up about 22% from ₹1,181.42 crore in FY24. Full-year standalone net profit came in at ₹63.79 crore, sharply lower than ₹199.45 crore last year, mainly because of a ₹115.14 crore exceptional loss (impairment of investments in subsidiaries). EBITDA grew strongly to ₹454.06 crore from ₹335.81 crore, with margins expanding. Operating cash flow was healthy at ₹334.02 crore. The Board recommended a final dividend of ₹1 per share (10% of face value). Auditor B S R & Co. LLP gave an unmodified (clean) opinion but included emphasis-of-matter notes on the ongoing SFIO investigation into pre-2018 transactions and the Supreme Court directions regarding RHT Health Trust deals. The company raised ₹1,550 crore via non-convertible debentures during the year, lifting the standalone debt-equity ratio to 0.22 from 0.07.
Strong revenue growth and improved EBITDA signal healthy core operations, but headline profits took a one-time hit from the subsidiary investment impairment. Shareholders get a modest dividend, while legacy legal overhangs (SFIO and Supreme Court matters) remain watch-points despite the clean audit opinion.